Loading
Built MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal.
David B. Solit is Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. He is known for building MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal. His selected paper reports the mutational landscape of metastatic cancer revealed by prospective clinical sequencing of 10,000 patients. His centre has sequenced tens of thousands of tumours to define actionable alterations, and he continues to study exceptional responders and bladder cancer genomics.
| Title | Journal | Year |
|---|---|---|
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients | Nature Medicine | 2017 |
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Memorial Sloan Kettering Cancer Center, Bladder & urothelial cancer.
Shares Memorial Sloan Kettering Cancer Center, Bladder & urothelial cancer.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.